Marshall Wace’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $452M | Buy |
16,082,788
+3,420,874
| +27% | +$91.1M | 0.45% | 22 |
|
|
2025
Q4 | $315M | Buy |
12,661,914
+5,682,612
| +81% | +$143M | 0.29% | 48 |
|
|
2025
Q3 | $178M | Buy |
6,979,302
+6,531,391
| +1,458% | +$161M | 0.18% | 83 |
|
|
2025
Q2 | $10.9M | Sell |
447,911
-13,641,127
| -97% | -$318M | 0.01% | 809 |
|
|
2025
Q1 | $357M | Buy |
14,089,038
+6,329,548
| +82% | +$166M | 0.45% | 33 |
|
|
2024
Q4 | $206M | Sell |
7,759,490
-6,970,717
| -47% | -$189M | 0.25% | 56 |
|
|
2024
Q3 | $426M | Buy |
14,730,207
+9,352,034
| +174% | +$273M | 0.52% | 20 |
|
|
2024
Q2 | $150M | Buy |
+5,378,173
| New | +$148M | 0.2% | 89 |
|
|
2024
Q1 | – | Sell |
-733,287
| Closed | -$20.3M | – | 2720 |
|
|
2023
Q4 | $21.1M | Sell |
733,287
-1,676,211
| -70% | -$50.7M | 0.04% | 470 |
|
|
2023
Q3 | $79.9M | Buy |
2,409,498
+2,017,709
| +515% | +$71.4M | 0.16% | 120 |
|
|
2023
Q2 | $14.4M | Buy |
391,789
+331,231
| +547% | +$12.9M | 0.03% | 599 |
|
|
2023
Q1 | $2.47M | Sell |
60,558
-619,116
| -91% | -$26.7M | 0.01% | 1336 |
|
|
2022
Q4 | $34.8M | Sell |
679,674
-3,351,413
| -83% | -$161M | 0.08% | 285 |
|
|
2022
Q3 | $176M | Sell |
4,031,087
-2,172,001
| -35% | -$106M | 0.39% | 35 |
|
|
2022
Q2 | $325M | Buy |
6,203,088
+3,836,099
| +162% | +$195M | 0.67% | 13 |
|
|
2022
Q1 | $123M | Sell |
2,366,989
-2,960,742
| -56% | -$154M | 0.23% | 82 |
|
|
2021
Q4 | $315M | Buy |
5,327,731
+3,778,140
| +244% | +$187M | 0.58% | 20 |
|
|
2021
Q3 | $66.6M | Buy |
1,549,591
+1,510,477
| +3,862% | +$66.9M | 0.28% | 57 |
|
|
2021
Q2 | $1.53M | Sell |
39,114
-791,097
| -95% | -$30.8M | 0.01% | 1593 |
|
|
2021
Q1 | $30.1M | Buy |
+830,211
| New | +$29.5M | 0.14% | 150 |
|
|
2020
Q2 | – | Sell |
-474,348
| Closed | -$14.7M | – | 1860 |
|
|
2020
Q1 | $14.7M | Sell |
474,348
-2,895,323
| -86% | -$98.7M | 0.15% | 151 |
|
|
2019
Q4 | $125M | Buy |
3,369,671
+2,045,020
| +154% | +$72.8M | 0.86% | 11 |
|
|
2019
Q3 | $45.2M | Buy |
+1,324,651
| New | +$48.2M | 0.36% | 57 |
|
|
2019
Q2 | – | Sell |
-690,645
| Closed | -$27.8M | – | 1728 |
|
|
2019
Q1 | $27.8M | Sell |
690,645
-48,031
| -7% | -$1.92M | 0.26% | 72 |
|
|
2018
Q4 | $30.6M | Buy |
738,676
+687,864
| +1,354% | +$28.6M | 0.31% | 58 |
|
|
2018
Q3 | $2.13M | Sell |
50,812
-9,107
| -15% | -$351K | 0.02% | 666 |
|
|
2018
Q2 | $2.06M | Sell |
59,919
-27,556
| -32% | -$942K | 0.03% | 423 |
|
|
2018
Q1 | $2.94M | Buy |
87,475
+34,754
| +66% | +$1.19M | 0.12% | 151 |
|
|
2017
Q4 | $1.81M | Buy |
52,721
+1,997
| +4% | +$68.1K | 0.08% | 194 |
|
|
2017
Q3 | $1.73M | Sell |
50,724
-148,292
| -75% | -$4.77M | 0.08% | 176 |
|
|
2017
Q2 | $6.42M | Buy |
199,016
+144,204
| +263% | +$4.55M | 0.28% | 73 |
|
|
2017
Q1 | $1.77M | Sell |
54,812
-2,084,065
| -97% | -$65.7M | 0.09% | 148 |
|
|
2016
Q4 | $65.9M | Buy |
+2,138,877
| New | +$65.3M | 0.43% | 54 |
|
|
2016
Q2 | – | Sell |
-2,032,414
| Closed | -$57.2M | – | 1120 |
|
|
2016
Q1 | $57.2M | Sell |
2,032,414
-3,150,715
| -61% | -$90M | 0.55% | 41 |
|
|
2015
Q4 | $159M | Buy |
5,183,129
+1,868,424
| +56% | +$58.8M | 1.49% | 6 |
|
|
2015
Q3 | $98.8M | Buy |
3,314,705
+1,356,085
| +69% | +$43.5M | 1.21% | 9 |
|
|
2015
Q2 | $62.3M | Sell |
1,958,620
-1,701,806
| -46% | -$55.5M | 0.81% | 19 |
|
|
2015
Q1 | $121M | Buy |
3,660,426
+707,173
| +24% | +$22.5M | 1.57% | 6 |
|
|
2014
Q4 | $87.3M | Buy |
2,953,253
+1,408,581
| +91% | +$40.4M | 1.15% | 9 |
|
|
2014
Q3 | $43.3M | Buy |
1,544,672
+1,164,995
| +307% | +$32.7M | 0.63% | 35 |
|
|
2014
Q2 | $10.7M | Sell |
379,677
-120,141
| -24% | -$3.42M | 0.16% | 178 |
|
|
2014
Q1 | $15.2M | Buy |
+499,818
| New | +$14.9M | 0.28% | 100 |
|
Other funds holding PFE
VCM
VPM
Marshall Wace's PFE Position: Q1 2026 in Review
Marshall Wace increased its Pfizer (PFE) stake by 27% in Q1 2026, buying an estimated $91.1M and bringing the position to 16,082,788 shares worth $452M. The position accounts for 0.45% of the portfolio, ranked #22.
Marshall Wace first reported a position in PFE in Q1 2014 and has held it in 42 quarters since. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Marshall Wace held 16,082,788 shares of Pfizer worth $452M as of Q1 2026.
- Marshall Wace bought 3,420,874 Pfizer shares in Q1 2026, an estimated $91.1M.
- Pfizer made up 0.45% of Marshall Wace's portfolio in Q1 2026, its #22 holding.
- Marshall Wace first reported a position in Pfizer in Q1 2014 and has held it in 42 quarters since.
- 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.